These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17127957)

  • 1. [Is it possible to treat bronchial carcinoma without chemotherapy?].
    Pujol JL
    Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S23-10S26. PubMed ID: 17127957
    [No Abstract]   [Full Text] [Related]  

  • 2. [New era in cancer therapy. Gefitinib: small molecule--strong action].
    Arnheim K
    MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
    [No Abstract]   [Full Text] [Related]  

  • 3. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
    Pérol M
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154
    [No Abstract]   [Full Text] [Related]  

  • 4. [Tyrosine kinase inhibitor erlotinib (Tarceva) improves survival of patients with multiple previous treatments].
    Krankenpfl J; 2004; 42(5-6):158. PubMed ID: 15527222
    [No Abstract]   [Full Text] [Related]  

  • 5. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 6. EGFR inhibition in NSCLC: the emerging role of cetuximab.
    Herbst RS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining targeted agents in lung cancer.
    Belani CP; Adjei A
    Clin Lung Cancer; 2004 Nov; 6(3):138. PubMed ID: 15555212
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
    Cho SH; Park LC; Ji JH; Park S; Hwang DW; Lee JY; Choi YL; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):315-20. PubMed ID: 22760226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 10. Directed therapies in lung cancer: new hope?
    Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
    Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current status of the study of the mechanism of epidermal growth factor receptor targeting drug therapy and their related markers].
    Wang Y; Xu JM; Song ST
    Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):573-6. PubMed ID: 16438862
    [No Abstract]   [Full Text] [Related]  

  • 13. Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
    DeGrendele H
    Clin Lung Cancer; 2003 Sep; 5(2):83-5. PubMed ID: 14596689
    [No Abstract]   [Full Text] [Related]  

  • 14. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Zalcman G; Bergot E
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217981
    [No Abstract]   [Full Text] [Related]  

  • 15. Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Myerson JS; Iqbal SA; O'Brien ME; Popat S
    Clin Lung Cancer; 2010 Sep; 11(5):E5-8. PubMed ID: 20837451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
    Sequist LV; Bell DW; Lynch TJ; Haber DA
    J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy for non-small cell lung cancer.
    D'Amico TA
    Semin Thorac Cardiovasc Surg; 2005; 17(3):195-8. PubMed ID: 16253822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
    Böker B; Lüders H; Grohé C
    Pneumologie; 2012 Feb; 66(2):89-95. PubMed ID: 22337328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.